EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy

Chuan Chen, Zehua Sun, Zening Wang iD, Seungmin Shin, Abigail Berrios, John W Mellors, Dimiter S Dimitrov, Wei Li

Antibodies · 07.05.2024 · 13 (2) · 39

DOI: 10.3390/antib13020039 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antibodies, online erschienen am 07.05.2024. Verfasst von Chuan Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA 15…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: St. Baldrick's foundation, UPMC, St. Baldrick’s foundation, D-Feet Cancer Dalton Fox Foundation Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The anaplastic lymphoma kinase (ALK, CD247) is a potential target for antibody-based therapy. However, no antibody-based therapeutics targeting ALK have entered clinical trials, necessitating the development of novel antibodies with unique therapeutic merits. Single-domain antibodies (sdAb) bear therapeutic advantages compared to the full-length antibody including deeper tumor penetration, cost-effective production and fast washout from normal tissues. In this study, we identified a human immunoglobulin heavy chain variable domain (VH domain) (VH20) from an in-house phage library. VH20 exhibits good developability and high specificity with no off-target binding to ~6000 human membrane proteins. VH20 efficiently bound to the glycine-rich region of ALK with an EC50 of 0.4 nM and a KD of 6.54 nM. Both VH20-based bispecific T cell engager (TCE) and chimeric antigen receptor T cells (CAR Ts) exhibited potent cytolytic activity to ALK-expressing tumor cells in an ALK-dependent manner. VH20 CAR Ts specifically secreted proinflammatory cytokines including IL-2, TNFα and IFNγ after incubation with ALK-positive cells. To our knowledge, this is the first reported human single-domain antibody against ALK. Our in vitro characterization data indicate that VH20 could be a promising ALK-targeting sdAb with potential applications in ALK-expressing tumors, including neuroblastoma (NBL) and non-small cell lung cancer.

Schlagwörter

Stichwörter der Autor:innen

ALKimmunotherapyphage displaysingle-domain antibodies

Autor:innen und Institutionen

  • Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA 15261, USA.
  • Institute of Molecular Medicine, University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
  • Department of Biological Sciences, University of Pittsburgh Kenneth P. Dietrich School of Arts and Sciences, Pittsburgh, PA 15260, USA.

ORCID-Profile: Zening Wang

Förderung

  • St. Baldrick's foundation
  • UPMC, St. Baldrick’s foundation
  • D-Feet Cancer Dalton Fox Foundation Grant

Zitieren

APA

Chen, C., Sun, Z., Wang, Z., Shin, S., Berrios, A., Mellors, J. W., Dimitrov, D. S., & Li, W. (2024). Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy. Antibodies, 13(2), 39. https://doi.org/10.3390/antib13020039

Vancouver

Chen C, Sun Z, Wang Z, Shin S, Berrios A, Mellors JW, et al. Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy. Antibodies. 2024;13(2):39. doi:10.3390/antib13020039

BibTeX
@article{Chen2024,
  author = {Chen, Chuan and Sun, Zehua and Wang, Zening and Shin, Seungmin and Berrios, Abigail and Mellors, John W and Dimitrov, Dimiter S and Li, Wei},
  title = {Identification of a Fully Human Antibody VH Domain Targeting Anaplastic Lymphoma Kinase (ALK) with Applications in ALK-Positive Solid Tumor Immunotherapy},
  journal = {Antibodies},
  year = {2024},
  volume = {13},
  number = {2},
  pages = {39},
  doi = {10.3390/antib13020039}
}
Kostenlos starten →